Novo Nordisk AS (WAR:NVO) Cyclically Adjusted Book per Share: zł11.03 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WAR:NVO Novo Nordisk AS WAR:NVO
68 GF Score
Price zł181.80
GF Value zł530.73
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is Novo Nordisk AS Cyclically Adjusted Book per Share?

Novo Nordisk AS WAR:NVO -6.92% 68 Cyclically Adjusted Book per Share is zł11.03 as of Mar. 2026. GuruFocus rates WAR:NVO with a GF Score™ of 68/100 and a GF Value™ of zł530.73 (Significantly Undervalued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Novo Nordisk AS's adjusted book value per share for the three months ended in Mar. 2026 was zł26.420. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is zł11.03 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Novo Nordisk AS's average Cyclically Adjusted Book Growth Rate was 21.50% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 16.20% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 15.60% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was 11.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Novo Nordisk AS was 16.20% per year. The lowest was 4.10% per year. And the median was 7.80% per year.

As of today (2026-08-02), Novo Nordisk AS's current stock price is zł181.80. Novo Nordisk AS's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was zł11.03. Novo Nordisk AS's Cyclically Adjusted PB Ratio of today is 16.48.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Novo Nordisk AS was 74.88. The lowest was 12.40. And the median was 25.19.


Novo Nordisk AS  (WAR:NVO) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Novo Nordisk AS's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=181.80/11.03
=16.48

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Novo Nordisk AS was 74.88. The lowest was 12.40. And the median was 25.19.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Novo Nordisk AS Cyclically Adjusted Book per Share Related Terms


Novo Nordisk AS Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Novo Nordisk AS's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novo Nordisk AS Cyclically Adjusted Book per Share Chart

Novo Nordisk AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 11.13

Novo Nordisk AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 9.56 9.94 11.13 11.03

WAR:NVO vs LLY, JNJ, ABBV: Cyclically Adjusted Book per Share Comparison

For the Drug Manufacturers - General subindustry, Novo Nordisk AS's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novo Nordisk AS Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Novo Nordisk AS's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Novo Nordisk AS's Cyclically Adjusted PB Ratio falls into.


WAR:NVO
68GF Score
Novo Nordisk AS WAR:NVO
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Novo Nordisk AS Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Novo Nordisk AS's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=26.42/121.6800*121.6800
=26.420

Current CPI (Mar. 2026) = 121.6800.

Novo Nordisk AS Quarterly Data

Book Value per Share CPI Adj_Book
201606 4.617 100.600 5.584
201609 4.556 100.200 5.533
201612 4.698 100.300 5.699
201703 4.241 101.200 5.099
201706 5.566 101.200 6.692
201709 5.719 101.800 6.836
201712 5.914 101.300 7.104
201803 5.622 101.700 6.726
201806 5.935 102.300 7.059
201809 5.758 102.400 6.842
201812 6.022 102.100 7.177
201903 5.600 102.900 6.622
201906 6.314 102.900 7.466
201909 6.165 102.900 7.290
201912 6.662 102.900 7.878
202003 6.401 103.300 7.540
202006 7.256 103.200 8.555
202009 7.572 103.500 8.902
202012 8.224 103.400 9.678
202103 7.575 104.300 8.837
202106 8.639 105.000 10.011
202109 8.529 105.800 9.809
202112 8.686 106.600 9.915
202203 8.090 109.900 8.957
202206 8.716 113.600 9.336
202209 8.430 116.400 8.812
202212 9.862 115.900 10.354
202303 9.535 117.300 9.891
202306 10.965 116.400 11.462
202309 11.108 117.400 11.513
202312 13.054 116.700 13.611
202403 12.063 118.400 12.397
202406 13.602 118.500 13.967
202409 15.046 118.900 15.398
202412 16.933 118.900 17.329
202503 16.869 120.200 17.077
202506 21.829 120.700 22.006
202509 22.445 121.600 22.460
202512 25.557 121.200 25.658
202603 26.420 121.680 26.420

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of zł11.03 mean?
Novo Nordisk AS (WAR:NVO) has a Cyclically Adjusted Book per Share of zł11.03 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Novo Nordisk AS and its competitors.
Is Novo Nordisk AS's Cyclically Adjusted Book per Share too high?
Novo Nordisk AS's current Cyclically Adjusted Book per Share is zł11.03. Overall, Novo Nordisk AS has a GF Score™ of 68/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Novo Nordisk AS's Cyclically Adjusted Book per Share compare to LLY and JNJ?
Novo Nordisk AS's Cyclically Adjusted Book per Share of zł11.03 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Book per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Novo Nordisk AS and its competitors. Novo Nordisk AS's current Cyclically Adjusted Book per Share is zł11.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novo Nordisk AS stock overvalued right now?
Based on GuruFocus' analysis, Novo Nordisk AS (WAR:NVO) is currently considered Significantly Undervalued. The stock's GF Value™ is zł530.73, compared to a current price of zł181.80 — trading 65.7% below its estimated fair value. The current Cyclically Adjusted Book per Share is zł11.03. Novo Nordisk AS's overall GF Score™ is 68/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Novo Nordisk AS (WAR:NVO), the current Cyclically Adjusted Book per Share is zł11.03 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Novo Nordisk AS (WAR:NVO) Overvalued in 2026?

Based on GuruFocus' analysis, Novo Nordisk AS stock appears to be undervalued. The current stock price of zł181.80 is trading 65.7% below its estimated GF Value™ of zł530.73. GuruFocus considers Novo Nordisk AS to be Significantly Undervalued.

Key valuation signals for WAR:NVO:

  • Cyclically Adjusted Book per Share: zł11.03
  • GF Value™: zł530.73 vs. price of zł181.80 (65.7% below fair value)
  • GF Score™: 68/100 with 4 warning signs

No single metric tells the full story. See the WAR:NVO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Novo Nordisk AS Business Description

Address Novo Alle 1, Bagsvaerd, DNK, 2880
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
68GF Score

Get the complete analysis for WAR:NVO

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł181.80
Price
zł530.73
GF Value